ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
- WESTMINSTER, Colo., Sept. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first international patient has been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. The patient was enrolled in Brazil. ARCA also plans to enroll patients from Argentina and is currently enrolling patients at multiple sites in the United States. The international Phase 2b trial is approximately 75% enrolled as of this date. The Company currently anticipates topline trial data in the fourth quarter of 2021.
- 09/16/2021
|
ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th
- WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Jeff Dekker, Chief Financial Officer, will present at the Q3 Virtual Investor Summit being held August 17-18, 2021.
- 08/16/2021
|
ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th
- WESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Thomas Keuer, Chief Operating Officer, will present at the Access to Giving Virtual Investor Conference, which is being held virtually July 13-15, 2021.
- 07/09/2021
|
Best Reddit Penny Stocks to Buy Now? 7 for Your July Small-Caps List
- Are these Reddit penny stocks the best 7 to watch in July 2021? The post Best Reddit Penny Stocks to Buy Now?
- 07/07/2021
|
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
- WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2021 financial results and provided a corporate update.
- 05/11/2021
|
Christopher Graybill Joins ARCA as Vice President, Clinical Development
- WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development.
- 05/05/2021
|
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer
- WESTMINSTER, Colo., May 03, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced C. Jeff Dekker as its Chief Financial Officer, effective May 10, 2021, following Brian Selby's planned departure after 14 years of service with the Company.
- 05/03/2021
|
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
- WESTMINSTER, Colo., March 18, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2020 financial results and provided a corporate update.
- 03/18/2021
|
3 Net-Net Working Capital Stocks
- There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed the share prices near or above the liquidation value. Should the company fail, these shareholders would, in theory, still be able to make money due to a difference between the liquidation value and purchasing price.
- 02/16/2021
|
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
- WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company's offices located at 10170 Church Ranch Way, Suite 100, Westminster, CO 80021, approximately one-quarter mile from the previously noticed location. The meeting location change is due to the COVID-19 related unavailability of the previously noticed meeting location.
- 12/09/2020
|
ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment
- Shares of ARCA Biopharma Inc. gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug Administration for its mid-stage experimental COVID-19 treatment. ARCA plans to launch a Phase 2b clinical trial enrolling 100 hospitalized COVID-19 patients next month, and it anticipates that the first round of topline data from the study will be available in the second quarter of next year.
- 11/23/2020
|
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
- WESTMINSTER, Colo., Nov. 23, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of AB201 as a potential treatment for COVID-19. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with COVID-19 in December 2020, with topline trial data anticipated in the second quarter of 2021.
- 11/23/2020
|
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
- WESTMINSTER, Colo., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial results for the third quarter of 2020 and provided a corporate update.
- 11/02/2020
|
How to watch the Le Mans 24 Hours online and on TV this weekend
- Everything you need to know about the 88th running of the Le Mans 24 Hours
- 09/17/2020
|
COVID - 19 Impact Analysis for Global Demolition & Wrecking Market Report on Pricing Trends and Strategies, Supplier Market Insights, Forecast For 2024 by Spendedge
- The Demolition and wrecking market will register an incremental spend of about $ 10 billion, growing at a CAGR of 3.52% during the five-year forecast
- 09/17/2020
|
We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth
- We can readily understand why investors are attracted to unprofitable companies. For example, although...
- 08/17/2020
|
VBL Therapeutics' Cancer Drug, And Other News: The Good, Bad And Ugly Of Biopharma
- VBL Therapeutics reports progress for ovarian cancer drug candidate. ARCA Biopharma announces mid-stage study for COVID-19 candidate.
- 08/13/2020
|
ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19
- * ARCA anticipates filing an IND for AB201 for COVID-19 in September 2020 and initiating Phase 2B clinical testing as early as Q4 2020WESTMINSTER, CO / ACCESSWIRE / August 12, 2020 / ARCA biopharma, Inc.
- 08/12/2020
|
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
- Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. * AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseases * ARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4 2020WESTMINSTER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial results for the second quarter of 2020 and provided a corporate update.Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “As the SARS-CoV-2 pandemic has progressed, serious complications relating to over-activation of the coagulation and immune systems have increasingly been observed in patients hospitalized with severe disease. Based on previous and emerging work on mechanisms of virus pathogenesis, we believe this evidence implicates involvement of tissue factor pathways, of which AB201 is a potent and long-acting inhibitor, providing a strong rationale to evaluate AB201 as a potential therapeutic for COVID-19. With this rationale along with significant safety data from prior human clinical trials, we look forward to initiating Phase 2 clinical development later this year.”Pipeline UpdateAB201 (rNAPc2) – a small recombinant protein being developed as a potential treatment for RNA virus associated disease, initially focusing on COVID-19. * Initiated planning for development of AB201 as a potential treatment for patients with severe COVID-19. * Clinical collaboration established with the Colorado Prevention Center, the University of Colorado's Academic Research Organization. * The Company anticipates filing an Investigational New Drug (IND) application for AB201 as a potential treatment for COVID-19 with the U.S. Food and Drug Administration (FDA) in third quarter of this year. * Pending FDA concurrence, ARCA estimates initiating Phase 2 clinical testing of AB201 in the fourth quarter of this year.GencaroTM (bucindolol hydrochloride) - a pharmacologically unique beta-blocker and mild vasodilator being developed as a potential genetically targeted treatment for atrial fibrillation (AF) in patients with heart failure (HF). * Initiation of the PRECISION-AF Phase 3 clinical trial is on hold due to the ongoing COVID-19 pandemic and prioritizing the development of AB201. ARCA estimates that enrollment in PRECISION-AF could start in 2021; however, this estimate is subject to change due to the uncertainties of the ongoing COVID-19 pandemic and the availability of patients for non-COVID-19 related clinical trials. Any future development of Gencaro, including initiating any Phase 3 clinical trial, is dependent on obtaining additional financing. * The FDA has issued a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial (PRECISION-AF) to examine Gencaro as a genetically targeted therapy for the prevention of AF recurrence in certain heart failure patients.Second Quarter 2020 Summary Financial Results Cash and cash equivalents were $11.0 million as of June 30, 2020, compared to $8.4 million as of December 31, 2019. ARCA believes that its current cash and cash equivalents, together with net proceeds of $24.1 million raised in July from sales of its common stock, will be sufficient to fund its operations, at its current cost structure, plus projected costs for the AB201 clinical development program, through the end of the fourth quarter of 2021.Research and development (R&D) expense for the three months ended June 30, 2020 was $0.4 million compared to $0.4 million for the corresponding period of 2019, a decrease of approximately $68,000. R&D expense for the six months ended June 30, 2020 was $0.7 million compared to $1.1 million for the corresponding period of 2019, a decrease of approximately $0.4 million.R&D personnel costs decreased approximately $0.1 million for the three months ended June 30, 2020, as compared to the corresponding period of 2019. R&D personnel costs decreased approximately $0.3 million for the six months ended June 30, 2020, as compared to the corresponding period of 2019. The remaining decrease is primarily a result of lower outside services and consulting costs.General and administrative (G&A) expenses were $0.9 million and $1.1 million for the three months ended June 30, 2020 and 2019, respectively. The $0.1 million decrease was primarily a result of lower personnel costs and lower outside services and consulting costs in 2020. G&A expenses were $1.9 million and $2.2 million for the six months ended June 30, 2020 and 2019, respectively. The $0.3 million decrease was primarily a result of lower personnel costs and lower outside services and consulting costs in 2020.Total operating expenses for the three months ended June 30, 2020 were $1.3 million compared to $1.5 million for the corresponding period in 2019. Total operating expenses for the six months ended June 30, 2020 were $2.7 million compared to $3.3 million for the corresponding period in 2019.Net loss for the three months ended June 30, 2020 was $1.3 million, or $0.73 per basic and diluted share, compared to $1.4 million, or $1.14 per basic and diluted share, for the corresponding period in 2019. Net loss for the six months ended June 30, 2020 was $2.6 million, or $1.55 per basic and diluted share, compared to $3.1 million, or $2.87 per basic and diluted share, for the corresponding period in 2019.The Company will need to raise additional capital, and/or complete a partnership or other possible strategic transaction, to fund future operations and develop AB201 and Gencaro or any other product candidates.About ARCA biopharma ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing AB201 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. ARCA is also developing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit www.arcabio.com or follow the Company on LinkedIn.Safe Harbor Statement This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of ARCA’s financial resources to support its operations through the end of the fourth quarter of 2021, potential future development plans for AB201 and Gencaro, the expected features and characteristics of AB201 and Gencaro, including the potential for genetic variations to predict individual patient response to Gencaro, Gencaro’s potential to treat atrial fibrillation, AB201’s potential to treat COVID-19 or CAC, future treatment options for patients with COVID-19, or AF, and the potential for Gencaro to be the first genetically targeted AF prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA’s financial resources and whether they will be sufficient to meet its business objectives and operational requirements; ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of AB201 or Gencaro or to otherwise continue operations in the future; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the Securities and Exchange Commission, including without limitation ARCA’s annual report on Form 10-K for the year ended December 31, 2019, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.Investor & Media Contact: Derek Cole 720.940.2163 derek.cole@arcabio.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/af496e97-20da-420a-bf93-e51b3a3ed740ARCA BIOPHARMA, INC. BALANCE SHEET DATA (in thousands) (unaudited) June 30, 2020 December 31, 2019 Cash and cash equivalents $11,041$8,363 Working capital $10,245$7,554 Total assets $11,633$8,536 Total stockholders’ equity $10,305$7,610 ARCA BIOPHARMA, INC.
- 08/05/2020
|
605 Days Later: How ArCoins Got the SEC Go-Ahead as an Ethereum-Traded Treasurys Fund - CoinDesk
- A look inside Arca and TokenSoft’s 605-day crusade to register the first Ethereum blockchain-native ‘40 Act Fund with the SEC.
- 07/29/2020
|
The Dollar Drop May Have Helped Push Bitcoin Past $11K
- Renewed pessimism about the greenback and the possibility of additional money printing may have pushed Bitcoin to a new 2020 high.
- 07/28/2020
|
Arca Labs Gets Approval from SEC to Operate Ethereum-Based Fund
- Arca Labs, a Los Angeles-based money manager, after 2 years got an “Notice of Effectiveness” from the SEC to operate its Treasury Fund.
- 07/07/2020
|
SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators
- The University of Colorado Anschutz Medical Campus and ARCA biopharma, Inc. (ABIO) today announced that the paper entitled "Dynamic Regulation of SARS-CoV-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium" (Bristow MR, et al. https://doi.org/10.1016/j.jacbts.2020.06.007 was published in JACC: Basic to Translational Science (JBTS), a member of the Journal of the American College of Cardiology (JACC) family of journals. The paper provides new information on mechanisms involved in host cell binding and entry of the SARS-CoV-2 in the human heart. Investigators affiliated with the Bristow Laboratory at CU Anschutz Medical Campus, Cardiovascular Institute at the University of Colorado School of Medicine and ARCA biopharma determined how known and potential mechanisms responsible for COVID-19 infection in the intact heart are altered by prior heart muscle disease, and to what extent they are changed when damaged heart muscle improves through a process called reverse remodeling.
- 07/07/2020
|
Crypto Fund Gives Ethereum Tokens Instead of Shares to Investors, And It’s Approved by the U.S. SEC | BTCMANAGER
- A 2018-founder crypto firm just got the green light from the U.S. SEC to function as an Ethereum-issuing investment fund on Monday, in a first such structure. Own a Hedge Fund’s Tokens Based in Los Angeles, Arca is an asset management firm that creates and manages institutional-grade products using crypto…
- 07/07/2020
|
Trading Begins for New Treasury-Based, SEC-Registered Digital Security
- Trading Begins for New Treasury-Based, SEC-Registered Digital Security
- 07/06/2020
|
Is Bitcoin About to Experience Unprecedented Volatility? | Live Bitcoin News
- Many analysts believe that bitcoin is on the verge of experiencing increased volatility as the coronavirus continues to affect economies.
- 07/01/2020
|
The Walking Dead: Beta's killer 'revealed' as actor drops huge season 10 finale spoiler
- THE WALKING DEAD season 10 finale cannot come soon enough for fans of the AMC horror after it was put on a hold as a result of the coronavirus pandemic. However, ahead of its return, one of the show's stars may have just given away one of the biggest spoilers yet.
- 07/01/2020
|
First Mover: Bitwise Calls $50K Bitcoin Price When Market Calm Finally Breaks - CoinDesk
- In the calm before the storm, Bitwise suggests Bitcoin could be looking at territory well north of the previous $20,000 all-time high.
- 06/30/2020
|
Arca: Kick I review – dissonance meets overground ambitions
- The Venezuelan electronic innovator adds guests and party tunes to her trademark glitchy sounds
- 06/28/2020
|
Harvick breaks through at Pocono
- Kevin Harvick gets his first Cup Series victory at Pocono Raceway in his 39th try, leaving just one track where he has never won.
- 06/28/2020
|
Kevin Harvick knocks Pocono from winless list in NASCAR’s first of 2 weekend Cup races
- Harvick snapped an 0-for-38 drought at Pocono, taking the checkered flag Saturday at one of two tracks where victory had eluded him.
- 06/28/2020
|
Late scratch: Harvick knocks off Pocono from winless list | MarketScreener
|
Late scratch: Harvick knocks off Pocono from winless list
- LONG POND, Pa. (AP) - Kevin Harvick hit pause on that victory swirl of scorched rubber and billows of smoke at Pocono Raceway. Sure, Harvick needed to save the engine for a repeat run in the same Ford and a shot at a weekend sweep in a Cup Series twin bill. He stood on his car alone again in victory lane in front of another race with barren grandstands and the only noise at the track just a few cheers from his Stewart-Haas Racing crew.
It's not much of a blowout if there's no one at the party.
"I'm not doing anymore celebrations with nobody out there to celebrate with," Harvick said. "Until the fans come back, I'm not doing a burnout, I'm not standing on the car, I'm not doing any of that stuff. It doesn't feel right not having my team in victory lane."
Harvick snapped an 0-for-38 drought at Pocono, taking the checkered flag Saturday at one of two tracks where victory had eluded him.
Harvick won the first of two NASCAR Cup races in front of no fans this weekend at Pocono and will start 20th on Sunday with the field set by inverting the lead-lap finishers.
The 44-year-old California driver has won at every active track except Kentucky Speedway (nine tries) and the 2014 series champion has three wins overall for SHR this season. He has three career wins at Charlotte Motor Speedway, though he's lost two races on the roval configuration.
Harvick held off a hard-charging Denny Hamlin, whose efforts were hampered by a late vibration, for his 52nd career Cup victory. He had 12 top-five finishes in his other 38 starts at Pocono.
"That's great to finally check Pocono off the list," Harvick said.
Aric Almirola was third, followed by Christopher Bell and Kyle Busch.
Ryan Preece finished 20th and will start on the pole Sunday. Teams brought cars straight to...
- 06/28/2020
|
Late scratch: Harvick knocks off Pocono from winless list
- LONG POND, Pa. (AP) — Kevin Harvick snapped an 0-for-38 drought at Pocono Raceway, taking the checkered flag Saturday at one of two tracks where victory had eluded him. Harvick won the first...
- 06/27/2020
|
Cup Series doubleheader at Pocono loses some luster
- Track officials and drivers were looking forward to a festive weekend before the pandemic hit, preventing fans from attending.
- 06/27/2020
|
Pocono twin bill weekend loses luster with no fans at track - The Boston Globe
- The absence of spectators stings a bit more for a track that will hold two races this weekend.
- 06/27/2020
|
Arca & Sophie’s ‘La Chíqui’ Pushes Pop Music Further Into the Future
- The producers team up after circling each other for years.
- 06/26/2020
|
Pocono twin bill weekend loses luster with no fans at track
- LONG POND, Pa. (AP) — The billboard at the entrance to Pocono Raceway has photos of Chase Elliott and Kyle Busch and “First-Ever NASCAR Doubleheader” in bold letters. The kicker comes at the...
- 06/26/2020
|
Arca launches a thrilling attack on genre with KiCk i
- “I do what I wanna do when I wanna do it / B****, I got the bags to prove it”. Arca has every right to sound so self-assured on the opening two lines of KiCk i — the Venezuelan’s work with Frank Ocean, FKA twigs and others marked her out as one of the most influential producers of the 2010s.
- 06/26/2020
|
DeFi Effect: Scaling Debate Begins as Ethereum Fees Reach Two-Year Highs | NewsBTC
- Ethereum has seen a decentralized finance craze over recent weeks.
- 06/26/2020
|
Crypto AM’s community play their part in the war against COVID-19 - CityAM
- Ever since the Crypto AM Awards 2020 on the 11th March and the subsequent lockdown enforcement, it was clear that
- 06/25/2020
|
Arca: KiCk i review – joyful sonic vision of what pop could be
- Alejandra Ghersi’s new set is a subversive and mischievous fusion of aural fireworks and psychedelic lyricism aided by Björk, Shygirl, Rosalía and Sophie
- 06/25/2020
|
2 ETFs for easy investing and good returns
- Here are 2 ETFs easy investing and good returns. One of those picks is BetaShares Global Sustainability Leaders ETF (ASX:ETHI).
- 06/25/2020
|
FTX Is Building Lots of Sophisticated Markets Few Traders Use - CoinDesk
- FTX has launched eight unique index futures and volatility markets in less than 12 months. But few traders use these markets.
- 06/24/2020
|
Una hermandad católica limpia la estatua de fray Junípero vandalizada en Palma
- La escultura había sido atacada en la madrugada del lunes con pintura roja, con la que se escribió la palabra «racista» en la base del monumento
- 06/23/2020
|
Una hermandad católica limpia la estatua de fray Junípero vandalizada en Palma
- La escultura había sido atacada en la madrugada del lunes con pintura roja, con la que se escribió la palabra «racista» en la base del monumento
- 06/23/2020
|
Back to business » AirInsight
- Sunday, June 21. We are well into June now and many airlines have significantly ramped up capacity again after the disastrous months of April and May. Capacity is still far below pre-Covid 19 levels but from June 1 and even more since June 15, there has been some serious flying again. Time to update our […]
- 06/23/2020
|
Burundi: Bunyoni na Bazombanza aba mbere bemejwe muri leta ya Ndayishimiye - BBC News Gahuza
- Alain-Guillaume Bunyoni yari asanzwe ari umushikiranganji w'umutekano kuva mu 2015. Yagirizwa uruhara mu bikorwa vy'ihonyanga ry'agateka ka zina muntu mu ngorane za politiki zo mu 2015.
- 06/23/2020
|
Macro Investors Ari Paul, Spencer Bogart and David Nage - CoinDesk
- Some of the smartest investors in the crypto space share how they think the larger macro context is shaping interest in bitcoin and digital assets.
- 06/22/2020
|
Back to business » AirInsight
- June is on the calendar, which means airlines have targeted a slow but progressive return to flying after two months of almost no activity. They include airlines in Europe but Singapore Airlines has planned a progressive return to business.
- 06/21/2020
|
RS Latin Music Picks: Week of June 15th
- Click here to read the full article.
Could your weekend playlist use a little more seasoning? Rolling Stone Latin selects some of the best new music releases from Latin America, Spain and Portugal. Keep track of the latest in Latin via our playlist on Spotify .
Arca, "Mequetrefe"
La Doña Arca spins critical gender theory in her latest track - then adds a little bounce for the club. Her head-spinning new song "Mequetrefe," the Spanish equivalent of a "do-nothing" in her native Venezuela, encapsulates both tensions of sound and gender. According to the artist, the song "invokes the tenderness behind expressing who you are without shame, and the confidence and bravery it requires, because expression of gender-nonconforming self-states in a public space can often result in static within your environment." The song features in her upcoming album, KiCk i, which comes out June 26th on XL Recordings.
More from Rolling Stone
Anuel AA Would Like to Reintroduce Himself in New 'Emmanuel' LP
Brazilian Pop Star Anitta...
- 06/19/2020
|
If Crypto Is Anything Like Fixed-Income, It's Going to Need a Fatter Textbook - CoinDesk
- Expect digital assets investing to mirror fixed income investing and become more specialized and complex over time, says our columnist.
- 06/16/2020
|
Google running survey on top Android 11 Beta 1 issue - 9to5Google
- In launching Android 11 Beta 1 last week, Google dramatically expanded the number of users testing the next OS. An Android 11 Beta survey...
- 06/16/2020
|
Google Turns To Pixel Users For Help With Android 11
- If you are a Pixel owner running the Android 11 Beta 1, then Google needs your help.
- 06/16/2020
|
“I lost $ 1 million the same week I won it the first time,” says a Wall Street trader - OBN
- Photo: Shutterstock Investment director Jeff Dorman shared one of his experiences in the financial market, when he lost more than $ 1 million for the…
- 06/14/2020
|
Android 11 adds a hidden trash folder to recover your files - 9to5Google
- With Android 11, Google has quietly introduced a new trash folder which can help keep your photos and more from being accidentally deleted.
- 06/12/2020
|
Here's Why Ethereum Is a Poor Investment According to Fund Managers
- The past few months have seen investment demand for Ethereum increase strongly. Nothing shows this as well as Grayscale's Ethereum Trust, a regulated and
- 06/12/2020
|
Android 11 Beta 1 hands-on: Top new features [Video] - 9to5Google
- We've ranked all of the best new features that have been added to Google Pixel devices as part of the Android 11 Beta 1 update.
- 06/11/2020
|
ARCA biopharma Shares Resume Trade, Continue Higher, Now Up 22.5%
|
ARCA biopharma Shares Spike Sharply Higher, Up 14%, Halted On Circuit Breaker
|
ARCA biopharma 13G Filing From Altium Capital Shows 9.99% Stake
|
Here’s everything new in Android 11 Beta 1 [Gallery] - 9to5Google
- The first four Android 11 Developer Previews were chock-full of new features and interface tweaks. Android 11 Beta 1 today brings the next version...
- 06/10/2020
|
Google brings wireless debugging, more for Android devs - 9to5Google
- With Android 11 Beta 1, Google has brought some improvements for developers, including wireless debugging support, a Jetpack Compose update, and more.
- 06/10/2020
|
Google launches Android 11 Beta 1 for Pixel phones - 9to5Google
- In recent years, Google has taken to previewing the next version of Android several months before I/O. The Android 11 Beta launch...
- 06/10/2020
|
Tech entrepreneur Scott Fletcher MBE invests in manchester Start-Up
- It’s a tough time for all businesses, but Manchester once again proves to be a hotspot for emerging new talent.
- 06/10/2020
|
Start-up wants to 'take the hassle' out of shirt shopping
- The Shirt Society has been launched by Matt Bird supplying a range of both formal and casual shirts on a rolling monthly subscription
- 06/10/2020
|
Robinhood traders cash in on the market comeback that billionaire investors missed
- Retail investors capitalized on the market comeback, buying into some of the most beaten down names from the coronavirus downturn.
- 06/09/2020
|
Walking Dead: Every Dead Comic Character Still Alive In The Show
- Several of them have lived longer than expected.
- 06/07/2020
|
Building a $100,000 portfolio with Afterpay shares and 3 other ASX companies
- Here's why I would include Afterpay Ltd (ASX: APT) shares when building a $100,000 ASX portfolio for long-term growth and returns.
- 06/05/2020
|
10 Musicians (and Then Some) Donating Toward Racial Justice on Bandcamp Today
- Plus 24 other musician and label recommendations, some of whom are also donating.
- 06/05/2020
|
NASCAR announces another wave of races through August
- CHARLOTTE, N.C. (AP) - NASCAR's All-Star Race will be a midweek event on July 15 at Charlotte Motor Speedway as part of a new revision to the schedule that runs through the first weekend of August.
NASCAR already has rescheduled races through June 21 and the update released Thursday begins the next weekend at Pocono Raceway in Pennsylvania. The track will host ARCA, the Truck Series, two Cup Series races on consecutive days, June 27-28, and the Xfinity Series.
NASCAR will then move to Indianapolis Motor Speedway for a July 4 weekend event combined with the IndyCar Series. Then it is on to Kentucky Speedway, the All-Star Race and then Texas Motor Speedway.
Kansas Speedway will host the Cup Series for a Thursday night race July 23.
New Hampshire will host the Cup Series on Aug. 2 in the final event announced in this latest revised schedule. NASCAR canceled eight points races in the Cup Series and the All-Star Race during a 10-week shutdown for the coronavirus pandemic.
NASCAR has so far run nine national series events - five in the Cup Series - since it resumed May 17 without spectators.
NASCAR made no mention if spectators will be allowed at any of the events - Indianapolis Motor Speedway, Kentucky and Pocono all said Thursday their events would not have fans, while Kansas said it is currently not expecting spectators. NASCAR senior leadership has not been available for public comment since May 17.
The revisions announced Thursday:
- Friday, June 26 at Pocono: ARCA
- Saturday, June 27 at Pocono: Trucks
- Saturday, June 27 at Pocono: Cup
- Sunday, June 28 at Pocono: Xfinity
- Sunday, June 28 at Pocono: Cup
- Saturday, July 4 at Indianapolis: Xfinity
- Sunday, July 5 at Indianapolis: Cup
-...
- 06/04/2020
|
NASCAR announces another wave of races through August
- CHARLOTTE, N.C. (AP) — NASCAR's All-Star Race will be a midweek event on July 15 at Charlotte Motor Speedway as part of a new revision to the schedule that runs through the first weekend of...
- 06/04/2020
|
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering
- ARCA biopharma, Inc. (ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the closing of its previously announced registered direct offering with certain institutional and accredited investors of 348,000 shares of ARCA’s common stock, at a purchase price of $9.00 per share, and pre-funded warrants to purchase 325,500 shares of common stock at a purchase price of $8.999 per warrant. The gross proceeds to ARCA, before deducting placement agent fees and other offering expenses, were approximately $6.1 million. The gross proceeds represent a mutually agreed reduction in the gross proceeds of the offering from the initial $9.4 million previously announced on June 1, 2020.
- 06/03/2020
|
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
- The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.
- 06/03/2020
|
71 Biggest Movers From Yesterday
|
Sabby Management 13G Shows Firm Took 9.99% Passive Stake In ARCA Biopharma As Of June 1
|
48 Stocks Moving In Monday's Mid-Day Session
|
ARCA Biopharma shares are trading lower after the company announced a $9.4 million registered direct offering at $9 per share.
|
ARCA Biopharma Announces $9.4M Registered Direct Offering At $9 Per Share
|
ARCA Biopharma Announces $9.4 Million Registered Direct Offering
- ARCA biopharma, Inc. (ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that it has entered into a definitive securities purchase agreement with certain institutional and accredited investors to purchase, in a registered direct offering, 348,000 shares of ARCA’s common stock, at a purchase price of $9.00 per share, and pre-funded warrants to purchase 694,222 shares of common stock at a purchase price of $8.999 per warrant. The gross proceeds to ARCA, before deducting placement agent fees and other offering expenses, are expected to be approximately $9.4 million. JonesTrading Institutional Services LLC is acting as the exclusive placement agent for the offering.
- 06/01/2020
|
26 Stocks Moving in Monday's Pre-Market Session
|
72 Biggest Movers From Friday
|
Key Derivatives Data Show Crypto Investors Are Finally Betting on a Rally
- The past few months and years have seen derivatives become increasingly important to crypto. This is largely due to the introduction of more
- 05/30/2020
|
The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight
- Biotech stocks could not sustain the uptrend in the holiday-shortened week, even as traders digested COVID-19-related news flow, clinical readouts, ASCO presentations and a few...
- 05/30/2020
|
A Mighty May: Over $200,000 In Gross Profits
- I'm happy to say that it looks like I'm poised to close out a second month in a row with zero red days. Not only that, but I've also logged another massive winning day on Thursday that, at one point, would've been my biggest green day ever. But, after giving up some profits, it only clocks in as my second-best day ever following last week's stellar $47,000 day.Still, between those huge wins and the series of solid green days throughout May, I've managed to surpass $200,000 in gross profits on the month. And if you look at my results over the course of this green streak, I'm closing in on $300,000 in just that span.For context, my gross profits for all of 2019 was $367,242, while in 2018, my best year ever, I clocked in at $499,826. We're not even halfway through the year and I'm already closing in on those figures. It's pretty incredible.My biggest single trade for the week, and also the year, was in ARCA biopharma, Inc. (NASDAQ: ABIO), which was a leading stock on my morning gap scanner gapping up 115% in premarket trading. Like last week's big trades in ShiftPixy, Inc. (NASDAQ: PIXY), ABIO was another low float stock moving on a headline.Despite being relatively thin, I decided to start trading ABIO daily aggressively from the start, taking a couple of premarket trades, one win and one loss, that effectively canceled each other out. At that point, I was getting nervous about being too aggressive too quickly but, especially once the bell rang and the stock chopped around somewhat in the pullback.However, the next green candle after the pullback squeezed up about 50 cents and by then I was looking for my entry on the next candle. I took a big 10,000 share position as the stock jumped another 40 cents and sold before it went into a halt. I took a few more trades following the halt as the stock pulled back again and I was up a little shy of $5,000..After those initial trades, all of which took place in the first 15 minutes of the day, the stock spent some time consolidating, but it didn't flush out and there was still a lot of activity in the order book. I waited for another big green candle and, at around 10 am, the stock started squeezing up again in what would be the biggest move of the day that pushed me close to the $20,000 mark. With that solid cushion, I just kept trading the pullbacks and gradually added profits a few thousand dollars at a time, trading an average share size of about 8,000 shares.It was an aggressive approach to the day, and I'm conscious of the fact that it resembles an attitude I've tried to limit in 2020. However, the stocks that I tend to trade have simply been on fire recently, and the results from the past month have given me plenty of capital to work with.Nevertheless, I'm going to try and moderate some of that enthusiasm heading into the new month and keep my share size more manageable, at least until I get a few more green days under my belt. If also you're looking for a fresh start in the new month, or you want to hone your trading for the summer, Warrior Trading is still in early enrollment for Summer School. For those interested, don't sleep on registering now for the 40% discount were running on all of our programs.See more from Benzinga * Another Day Trading Record, Shattered * Momentum's Still In Bloom In May As Summer Trading Approaches * Green Or Red: How To Handle A Streak(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/29/2020
|
Company News for May 29, 2020
- Companies In The News Are: ABIO, ARPO, LL, DLTR
- 05/29/2020
|
8-K: ARCA biopharma, Inc.
- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) --
Pursuant to Section 13 or 15(d)...
- 05/29/2020
|
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...
- 05/29/2020
|
Arca Biopharma Nearly Quintuples On Plans To Test A Coronavirus Drug
- Shares of Arca Biopharma nearly quintupled in value Thursday after the biotech company announced it would develop a coronavirus treatment for patients with abnormal blood clotting.
- 05/28/2020
|
Thursday’s Stock Market Close: US Equities Slip As Traders Weigh Grim Economic Data, China-Hong Kong Tensions
- U.S. stocks slipped on Thursday as China approved controversial security law for Hong Kong and 2 million more Americans filed jobless claims.
- 05/28/2020
|
Price Over Earnings Overview: ARCA biopharma
- In the current session, ARCA biopharma Inc. (NASDAQ: ABIO) is trading at $7.85, after a 98.73% spike. Over the past month, the stock increased by 114.48%, and in the past year, by 35.58%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 11.60%.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P; 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 0.03 in the biotechnology industry, ARCA biopharma has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * Golar LNG: Q1 Earnings Insights * Abercrombie & Fitch: Q1 Earnings Insights * Recap: ReWalk Robotics Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/28/2020
|
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
- AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients
- 05/28/2020
|
NetworkNewsBreaks – ARCA Biopharma, Inc. (NASDAQ: ABIO) Launches New Development Program to Evaluate AB201 for Treatment of COVID-19 Associated CAC
|
XRP Is Poised to Plunge Even Lower as Price Falls Under Two Crucial Supports
- There was a short period last week during which altcoins outperformed Bitcoin. Yet XRP and the rest of the cryptocurrency market have begun to
- 05/27/2020
|
Analyst: Ethereum is seriously undervalued right now for these fundamental reasons | CryptoSlate
- Since the peak of the last Bitcoin bubble in late-2017/early-2018, the vast majority of altcoins have collapsed dramatically from their all-time highs.
- 05/26/2020
|
Innovation Cycles, Crypto Venture Funds and Institutional Investors - CoinDesk
- Noelle Acheson urges us to pay attention to trends and cycles in venture capital investment, especially what it can tell us about crypto market cycles.
- 05/25/2020
|
What I Learned the First Time I Lost a Million Dollars - CoinDesk
- It doesn't take long to learn how to trade, but it takes a lifetime (and a harsh episode or two) to learn how to manage risk, says Jeff Dorman, CIO at Arca.
- 05/21/2020
|
Payments Provider Geidea Kicks Off Beta Testing of New Service for Saudi SMEs
- Geidea, a Saudi based payments company, has launched BETA testing for its new range of SME products. Geidea currently claims 70% market share in Saudi Arabia an
- 05/19/2020
|
RDC : la BCC et l’ARCA s’accordent pour mieux surveiller le marché financier
- Le renforcement de la surveillance du marché financier congolais et le contrôle des opérateurs oeuvrant dans ce secteur fondent le mémorandum d’entente que la Banque centrale du Congo (BCC) …
- 05/14/2020
|
El festival Sónar de Barcelona cancela su edición de 2020
- El festival de creatividad, tecnología y música avanzada Sónar ha comunicado hoy que, debido a la crisis global originada por la pandemia del Covid-19, ha suspendido la edición de
- 05/08/2020
|
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
- ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that clinical data evaluating Gencaro™ (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF) in patients with heart failure (HF) was presented at the 2020 Heart Rhythm Scientific Sessions, the annual scientific conference of the Heart Rhythm Society (HRS). While the in-person meeting was cancelled due to the continued global escalation of COVID-19, HRS has provided author presentations virtually through its online learning platform Heart Rhythm 365 and all abstracts will be published in a supplement to the May edition of the Heart Rhythm Journal.
- 05/07/2020
|
ARCA biopharma Highlights Presentation Of Clinical Data Evaluating Gencaro for Atrial Fibrillation Treatment In 2020 Heart Rhythm Scientific Sessions
|
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
- U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as.
- 05/06/2020
|
Google launches Android 11 Developer Preview 4, delays beta schedule due to coronavirus
- Google today launched Android 11 DP4 with app compatibility and performance improvements. Android 11 Beta 1 has been delayed until June 3.
- 05/06/2020
|
BPER Banca S p A : Group Results 1Q20 | MarketScreener
|
Google hosting Android 11 ‘Beta Launch Show’ next month - 9to5Google
- Google I/O 2020 developer conference was canceled due to COVID-19 and the company is turning to an Android 11 Beta Launch Show...
- 05/06/2020
|
ARCA biopharma Q1 EPS $(0.830) Up From $(1.860) YoY
|
Market Wrap: Bitcoin Edges Up to $7.7K as Mining Power Rebounds - CoinDesk
- Bitcoin’s price is on the upswing, and so is the computing power securing the network as a once-in-four-years event known as the halving approaches.
- 04/28/2020
|
Tesla releases new, highly anticipated Traffic Light and Stop Sign Control feature - Electrek
- Tesla has released a new, highly anticipated Traffic Light and Stop Sign Control feature. As we reported last month, Tesla has started to push an Autopilot update with the actual ability to handle intersections to some drivers in its “early access fleet,” a group of owners who beta test new software update from Tesla. We …
- 04/24/2020
|
La Catalunya rural reclama trabajo y más servicios para repoblarse
- Micropobles, que une a 170 municipios, busca soluciones sostenibles con ayuda institucional
- 04/20/2020
|
Behind The Scenes: Is Grayscale's Q1 $500 Million Spike Out Of Investor Interest Or Arbitrage?
- As the cryptocurrency market struggles to regain its footing to reach levels set earlier this year, Grayscale, a crypto investment firm largely focused on institutional investors announced a spike in its crypto assets inflows in its Q1 2020 report. The rapid growth in Grayscale’s crypto inflows to a record high of $500 million in Q1
- 04/18/2020
|
70 Biggest Movers From Yesterday
- Gainers
Arcus Biosciences, Inc. (NASDAQ: RCUS) shares surged 89.4% to close at $29.50 on Thursday amid Bloomberg report that Gilead is holding talks to take a stake in company....
- 04/17/2020
|
52 Stocks Moving In Thursday's Mid-Day Session
- Gainers
Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares climbed 167.8% to $92.90.
Edison Nation Inc (NASDAQ: EDNT) shares climbed 97.6% to $3.30 after the company...
- 04/16/2020
|
52 Stocks Moving In Thursday's Mid-Day Session
- Gainers
Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares climbed 167.8% to $92.90.
Edison Nation Inc (NASDAQ: EDNT) shares climbed 97.6% to $3.30 after the company...
- 04/16/2020
|
70 Biggest Movers From Yesterday
|
Digital Asset Trading Platforms in Chicago Establish Decentralized Finance Alliance to Work Closely on Open Finance Projects
- A group of Chicago-headquartered digital asset trading platforms are planning to work cooperatively, in order to connect more closely with Open Finance, or dece
- 04/08/2020
|
Jeff Dorman: Digital Assets Can Win in a Recession - CoinDesk
- Like gift cards, digital tokens represent claims on future services. In a downturn, those tokens may not lose value as readily as equities and debt.
- 04/06/2020
|
COVID-19 en RDC : l’ARCA et les sociétés d’assurances mettent à disposition 100.000 USD
- L’Autorité de Régulation et de Contrôle des Assurances en RDC (ARCA) et les sociétés d’assurances en République Démocratique du Congo, regroupées en Association des Sociétés d’Assurance et de Réa…
- 04/06/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ: BMRA ) Centogene NV (NASDAQ: CNTG ) Gilead Sciences, Inc. (NASDAQ: GILD ) Imara Inc (NASDAQ: IMRA ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aikido Pharma Inc (NASDAQ: AIKI ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Anika Therapeutics Inc (NASDAQ: ANIK ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Antares Pharma Inc (NASDAQ: ATRS ) Apyx Medical Corp (NASDAQ: APYX ) Arca Biopharma Inc (NASDAQ: ABIO ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) aTyr Pharma Inc (NASDAQ: LIFE ) AVEO Pharmaceuticals, Inc.
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
- 03/13/2020
|
Here's what would happen if coronavirus forces the NYSE to close its trading floor
- The New York Stock Exchange is prepared for the possibility that someone working on its trading floor may contract coronavirus.
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
RDC : l’Autorité Régulation et de Contrôle des Assurances (ARCA) agrée 3 nouvelles sociétés d’assurances et 3 autres en courtage !
- Réunie en conseil d’administration ce samedi 7 mars 2020, l’Autorité de Régulation et de Contrôle des Assurances (ARCA), a procédé à l’octroi de trois nouveaux agréments de société d’assurances et …
- 03/10/2020
|
Jeff Dorman: Crypto Needs a Value Investing Model - CoinDesk
- Before Warren Buffett and Benjamin Graham, speculation often drove valuations. Crypto needs a similar revolution in financial modeling.
- 03/10/2020
|
The Walking Dead Officially Makes Negan [SPOILER]
- Now what happens?
- 03/09/2020
|
Sunu obtient son agrément assurance non vie pour la RDC
- Le groupe Sunu poursuit son expansion continentale. En effet, la compagnie présidée par Pathé Dione vient de décrocher son agrément IARD pour la RDC, un marché de plus de 80 millions d’habitants. L…
- 03/07/2020
|
Daytona tweaks Speedweeks, moves Clash onto road course
- NASCAR will hit the road for its first race in 2021, part of a schedule shakeup that starts at Daytona International Speedway. The track announced several changes to the start of the annual...
- 03/04/2020
|
Google I/O 2020 get Cancelled due to Threat from Coronavirus - PhoneRadar
- Google I/O that happens every year in California was scheduled to take place on May 12 to 14th this year but to safety concerns, Google has to cancel the event. This event is aimed towards helping the developers with their work and announcing new products and like the MWC 2020, even the Google I/O has […]
- 03/04/2020
|
Benzinga Pro Review: Real-time Newsfeed vs Bloomberg vs Reuters
- Visit Benzinga Benzinga Pro Recommended For Those Who Want An Actionable Real-Time News Feed,
- 03/03/2020
|
140 Biggest Movers From Friday
|
TradingView Review: Charts, Screening & Costs Tested 2020
- Launch TradingView Best for U.S. & International Investors & Traders who Value a Huge
- 02/29/2020
|
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Feb. 27)
Global Cord Blood Corp (...
- 02/28/2020
|
140 Biggest Movers From Yesterday
|
WLL, SPEX, CODX and AIM among midday movers
- Gainers: iBio (NYSEMKT:IBIO) +131%.GAIN Capital Holdings (NYSE:GCAP) +66%.Vaxart (NASDAQ:VXRT) +57%.Co-Diagnostics (NASDAQ:CODX) +55%.Vir Biotechnology (NASDAQ:VIR) +51%.Allied Healthcare Products (NA
- 02/27/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
Tokenized US T-Bond Fund Seeks Foothold in $17T Market - CoinDesk
- The crypto industry is taking aim at one of Wall Street’s oldest redoubts: investing in the $17 trillion market for U.S. Treasury bonds.
- 02/26/2020
|
94 Biggest Movers From Friday
- Gainers
Trans World Entertainment Corporation (NASDAQ: TWMC) shares jumped 50.9% to close at $5.28 on Friday after the company disclosed that its subsidiary etailz entered into a...
- 02/24/2020
|
Stocks That Hit 52-Week Lows On Friday
- Friday's morning session saw 156 companies set new 52-week lows.
Facts of Interest:
Exxon Mobil (NYSE: XOM) was the biggest company on a market cap basis to set a...
- 02/21/2020
|
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.
- 02/21/2020
|
68 Stocks Moving In Friday's Mid-Day Session
|
Never Mind Hodlers, Crypto Needs More Opportunist Investors - CoinDesk
- The crypto markets need more investors who come and go and who aren't solely crypto investors, says CoinDesk columnist Jeff Dorman.
- 02/20/2020
|
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update
- U.S. FDA Special Protocol Assessment agreement for a single pivotal Phase 3 clinical trial (PRECISION-AF) of genetically-targeted GencaroPRECISION-AF clinical trial initiation.
- 02/18/2020
|
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update
- U.S. FDA Special Protocol Assessment agreement for a single pivotal Phase 3 clinical trial (PRECISION-AF) of genetically-targeted GencaroPRECISION-AF...
- 02/18/2020
|
ARCA Biopharma Reports FY19 EPS $(4.15) Vs. $(10.31) Year-Over-Year
|
Banks embrace cash recycling, ITMs to enhance branch ops
- Cash recycling and interactive teller machines are allowing banks and credit unions to create significant efficiencies at the branch level, with reduced staffing costs, increased productivity and reduced cash exposure, according to experts speaking at a panel on branch transformation at ATMIA's annual U.S. conference in Houston.
- 02/14/2020
|
85 Biggest Movers From Yesterday
- Gainers
China Pharma Holdings, Inc. (NYSE: CPHI) shares climbed 96.5% to close at $0.92 on Monday after gaining 11.50% on Friday.
Gulf Resources, Inc. (NASDAQ: GURE) shares...
- 02/04/2020
|
61 Stocks Moving In Monday's Mid-Day Session
- Gainers
China Pharma Holdings, Inc. (NYSE: CPHI) shares jumped 88% to $0.88 after gaining 11.50% on Friday.
Artelo Biosciences, Inc. (NASDAQ: ARTL) shares climbed 50.3% to $3.05...
- 02/03/2020
|
Does Market Volatility Impact ARCA biopharma, Inc.'s (NASDAQ:ABIO) Share Price?
- Anyone researching ARCA biopharma, Inc. (NASDAQ:ABIO) might want to consider the historical volatility of the share...
- 02/01/2020
|
What You Need to Know About Gold ETFs | Investing News Network
- Interested in investing in gold ETFs? Here's a breakdown of what you need to know about gold ETFs, from what they are to how they work.
- 01/14/2020
|
What is pro-BTC and is it good for Bitcoin and crypto adoption? | CryptoSlate
- The Bitcoin community — like many other online communities—is more often than not infatuated with memes and witty terms.
- 01/10/2020
|
La Pablo de Olavide implica a organizaciones comprometidas con la sociedad en el Día del Voluntariado
- La Universidad Pablo de Olavide ha celebrado el Día Internacional de Voluntariado, una cita destinada a sensibilizar a la comunidad universitaria sobre la importancia del compromis
- 12/05/2019
|
Nvidia Shield TV has a few known Disney+ issues - 9to5Google
- Disney+ just arrived this week and it's on Android TV from the get-go, but there are a few known issues with the service on Nvidia Shield TV devices.
- 11/13/2019
|
94 Biggest Movers From Yesterday
|
75 Stocks Moving In Thursday's Mid-Day Session
|
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
- PRECISION-AF pivotal Phase 3 clinical trial initiation anticipated first quarter of 2020Trial to examine atrial fibrillation in a heart failure population for which there are no.
- 11/06/2019
|
ARCA biopharma Q3 EPS $(0.76) Up From $(2.06) YoY
|
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Invest In Growth?
- We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- 11/03/2019
|
Bitcoin fails to recover as weekly volume on BitMEX drops 72% in 3 months, traders bearish
- The Bitcoin price has failed to push above a relatively low resistance level at $8,374, making a bigger pullback into the mid-$7,000 region more likely.
- 10/18/2019
|
Bitcoin volume on BitMEX drops to multi-month low, sparking fears of extended pullback
- The volume of bitcoin on BitMEX dropped to a seven-month low on October 12 (Saturday), to below $900 million for the first time since March.
- 10/14/2019
|
Block.one, Creator of EOS, Settles with the SEC. Was it a Slap on the Wrist? Did EOS Get a Pass from the Feds?
- Earlier this week it was announced by the Securities and Exchange Commission (SEC) that it had settled with Block.one, creator of EOS, regarding allegations of issuing unregistered securities during an initial coin offering (ICO) that raised a record-breaking $4 billion. The fine assessed by the
- 10/02/2019
|
Privacy Coins Face Existential Threat Amid Regulatory Pinch - AdvisorHub
- Cryptocurrencies such as Monero, Zcash and Dash, which can to varying degrees obfuscate transactions, are making it harder for exchanges and custodians to comply with fresh international guidelines to prevent illicit financing.
- 09/19/2019
|
RDC : la Société nationale de l’assurance obtient son agrément
- En République démocratique du Congo, l’Autorité de régulation et de contrôle des assurances (Arca) a octroyé début septembre, un agrément à la Société nationale de l’assurance (Sonas) qui devient a…
- 09/16/2019
|
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
- ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr. Michael Bristow, President and Chief Executive Officer of ARCA biopharma, will present at the “Excellence in Translational Science Symposium” at the Heart Failure Society of America (HFSA) 2019 Annual Scientific Meeting being held September 13-16 in Philadelphia. The presentation will focus on the development of novel anti-adrenergic therapeutics for atrial fibrillation and heart failure.
- 09/12/2019
|
71 Biggest Movers From Yesterday
|
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
- ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Gencaro atrial fibrillation clinical data from the GENETIC-AF Phase 2B trial have been selected for presentation at the Heart Failure Society of America (HFSA) 2019 Annual Scientific Meeting being held September 13-16 in Philadelphia. William T. Abraham, MD, FACP, FACC, College of Medicine Distinguished Professor, Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, will present the data.
- 09/11/2019
|
48 Stocks Moving In Wednesday's Mid-Day Session
|
Could The ARCA biopharma, Inc. (NASDAQ:ABIO) Ownership Structure Tell Us Something Useful?
- A look at the shareholders of ARCA biopharma, Inc. (NASDAQ:ABIO) can tell us which group is most powerful...
- 09/04/2019
|
Playing House: An Aggressive 40%+ Yielding Securities Lending Strategy
|
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. (“Abiomed” or “the Company”) (NASDAQ: ABMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- 08/21/2019
|
25 Healthcare Stocks Moving In Wednesday's Pre-Market Session
|
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
- FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction.
- 08/01/2019
|
ARCA biopharma Q2 EPS $(1.14) Up From $(2.74) YoY
|
Brave is introducing native Reddit and Vimeo tipping using crypto
- Brave Browser is introducing a new feature that will allow users to tip posters on Reddit and Vimeo using Basic Attention Token.
- 06/29/2019
|
51 Biggest Movers From Yesterday
|
42 Stocks Moving In Tuesday's Mid-Day Session
|
